🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity

RecruitingPhase 3Ages 4 Weeks - anyAllAssaf-Harofeh Medical Center
NCT06067958 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Preterm infants undergo serial eye examinations during their hospital stay to monitor for the development of a specific disease termed "retinopathy of prematurity". While those examinations are known to cause significant pain and stress, the current standard of care (sucrose and local anesthesia) is not adequate in terms of alleviation of pain. Purpose: The goal of this clinical trial is to test the effectiveness of dexmedetomidine for pain management in preterm infants undergoing routine eye examinations. The main questions it aims to answer are: * Does dexmedetomidine reduce the pain scores of preterm infants during and shortly after eye assessments in comparison to placebo (saline 0.9%). * Does dexmedetomidine cause more adverse effects than placebo. In this crossover study participants will receive either dexmedetomidine or saline 0.9% intranasally 30 minutes before t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Gestational age \< 31 weeks post-menstrual age, or birth weight \< 1500 grams * Informed consent signed by one of the parents Exclusion Criteria: * Invasive ventilation at the time of the eye assessment * Multiple congenital anomalies * Chromosomal / genetic anomalies * Infant received a sedative drug in last 5 days * Eye examination for reasons other than retinopathy of prematurity screening * Attending physician deemed the patient not stable enough
💊

What it tests

  • Dexmedetomidine
  • Saline
📍

Where

1 site
Assaf-Harofeh Medical Center
Be’er Ya‘aqov, Israel
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy